Table 2.
High cancer mortality rate in SARS-CoV-2–infected patients [32], [71], [72], [73], [74], [75], [76], [77], [78], [79], [80].
| Comorbidity | Italy | China | Overall (48% had comorbidity) | Mortality rate |
|---|---|---|---|---|
| Ischemic heart disease (%) | 30 | 5.8 | 8 | 10.5 |
| Diabetes (%) | 35.5 | 16.2 | 19 | 7.3 |
| Hypertension (%) | 76 | 23.7 | 22.2–26.9 | 6 |
| Active cancer (%) | 20.3 | 28 | 39 | 28.6 |
COVID-19 = coronavirus disease 2019; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.
Summary of data from (just in time) studies comparing demographic, clinical, treatment, and laboratory data from electronic medical health records between those who survived and those who succumbed to the disease. The analyses also tested serial samples for viral DNA. Overall, 91 (48%) of the 191 patients had comorbidities.